A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (ornithine phenylacetate) in the Treatment of Patients with Acute Liver Failure/Severe Acute Liver Injury (STOP-ALF) -- A Multi-Center Group to Study Acute Liver Failure

Project: Research project

Description

Evaluating the Safety and Tolerability of OCR-002 (ornithine phenylacetate) in the Treatment of Patients with Acute Liver Failure/Severe Acute Liver Injury (STOP-ALF) We expect to enroll 6 patients in this part of the project.
StatusActive
Effective start/end date9/18/158/31/19

Funding

  • University of Texas Southwestern Medical School (GMO-170910//5U01DK058369-19)
  • National Institute of Diabetes, Digestive and Kidney Diseases (GMO-170910//5U01DK058369-19)

Fingerprint

Acute Liver Failure
Safety
Liver
Wounds and Injuries
Therapeutics
ornithine phenylacetate